Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis

Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer.

[1]  A. Zullo,et al.  Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.

[2]  A. Blaes,et al.  Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.

[3]  J. Langton,et al.  Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987–2013) , 2015, Pharmacoepidemiology and drug safety.

[4]  Vered Stearns,et al.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Pearson,et al.  Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data , 2014, Asia-Pacific journal of clinical oncology.

[6]  Gerard J Fitzsimmons,et al.  From the Australian Institute of Health and Welfare , 2014, Communicable diseases intelligence quarterly report.

[7]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Amir Y. Shaikh,et al.  Chemotherapy-Induced Cardiotoxicity , 2012, Current Heart Failure Reports.

[9]  C. O’Malley,et al.  An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Body.  Increased fracture rate in women with breast cancer: a review of the hidden risk , 2011, BMC Cancer.

[11]  Christine Y. Lu,et al.  Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. , 2011, Journal of clinical epidemiology.

[12]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[13]  J. Farrar,et al.  Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors , 2009, Cancer.

[14]  N. Pavlidis,et al.  Effects of hormonal treatment on lipids in patients with cancer. , 2009, Cancer treatment reviews.

[15]  E. Roughead,et al.  Validity of medication‐based co‐morbidity indices in the Australian elderly population , 2009, Australian and New Zealand journal of public health.

[16]  Timothy L Lash,et al.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Verma,et al.  Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter , 2007, Breast Cancer Research and Treatment.

[18]  R. Baumgartner,et al.  Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Anne E Sales,et al.  Construction and Characteristics of the RxRisk-V: A VA-Adapted Pharmacy-Based Case-mix Instrument , 2003, Medical care.

[20]  Gwyn McClelland.  Survivors , 1891, The Hospital.

[21]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Scott Devine,et al.  Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer , 2010, Breast Cancer Research and Treatment.

[23]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.